tetano
Editor, Senior Moderator
Acta Cardiol
. 2023 Nov 30:1-7.
doi: 10.1080/00015385.2023.2286421. Online ahead of print. The effect of COVID-19 on the thromboembolic outcomes in atrial fibrillation patients in the long run
Serhat Karadavut[SUP] 1 [/SUP], Murat Cetin[SUP] 2 [/SUP], Omer Sahin[SUP] 1 [/SUP]
Affiliations
Background: While there has been a wealth of reports concerning the acute effects of the coronavirus disease 2019 (COVID-19), further information is needed to see how things unfold in the long run. This research aimed to ascertain whether the COVID-19 pandemic has increased the probability of thromboembolic events in atrial fibrillation (AF) patients.
Methods: In this retrospective study, we scanned 952 AF patients and classified 643 eligible ones per their history of catching COVID-19. Two hundred thirty-nine of 643 patients had a history of COVID-19 (Group 1), and 404 did not (Group 2). We then compared two years of thromboembolic events between the groups.
Results: Composite thromboembolic outcomes were seen in 76 (11.8%) patients. Of those, 32 (13.4%) were in Group 1, and 44 (10.8%) were in Group 2 (p = .03). 10 of 32 patients (31%) in Group 1 and 11 of 44 (25%) in Group 2 died because of thromboembolic events (p = .02). Histories of diabetes mellitus, chronic obstructive pulmonary disease, and COVID-19 independently predicted thromboembolic events in AF patients.
Conclusions: Having caught COVID-19 is likely to be associated with increased long-term thromboembolic outcomes in AF patients. Albeit the study design does not permit us to infer causality, our results question the necessity of more intensive anticoagulant therapy and closer follow-up in AF patients with past COVID-19.
Keywords: Atrial fibrillation; COVID-19; thromboembolism.
. 2023 Nov 30:1-7.
doi: 10.1080/00015385.2023.2286421. Online ahead of print. The effect of COVID-19 on the thromboembolic outcomes in atrial fibrillation patients in the long run
Serhat Karadavut[SUP] 1 [/SUP], Murat Cetin[SUP] 2 [/SUP], Omer Sahin[SUP] 1 [/SUP]
Affiliations
- PMID: 38032255
- DOI: 10.1080/00015385.2023.2286421
Background: While there has been a wealth of reports concerning the acute effects of the coronavirus disease 2019 (COVID-19), further information is needed to see how things unfold in the long run. This research aimed to ascertain whether the COVID-19 pandemic has increased the probability of thromboembolic events in atrial fibrillation (AF) patients.
Methods: In this retrospective study, we scanned 952 AF patients and classified 643 eligible ones per their history of catching COVID-19. Two hundred thirty-nine of 643 patients had a history of COVID-19 (Group 1), and 404 did not (Group 2). We then compared two years of thromboembolic events between the groups.
Results: Composite thromboembolic outcomes were seen in 76 (11.8%) patients. Of those, 32 (13.4%) were in Group 1, and 44 (10.8%) were in Group 2 (p = .03). 10 of 32 patients (31%) in Group 1 and 11 of 44 (25%) in Group 2 died because of thromboembolic events (p = .02). Histories of diabetes mellitus, chronic obstructive pulmonary disease, and COVID-19 independently predicted thromboembolic events in AF patients.
Conclusions: Having caught COVID-19 is likely to be associated with increased long-term thromboembolic outcomes in AF patients. Albeit the study design does not permit us to infer causality, our results question the necessity of more intensive anticoagulant therapy and closer follow-up in AF patients with past COVID-19.
Keywords: Atrial fibrillation; COVID-19; thromboembolism.